Since each us has previously published reviews of medication treat ment for adults and children with posttraumatic stress disorder (PTSD), [1 -3 ] we approach the subject somewhat differently in this arti cle. We ask and answer 11 questions that we believe encompass major con cerns of prescribing psychiatrists about medication treatment for adults or children with PTSD. We hope that this presentation provides a syn thesis of research literature in a form that directly addresses common clinical decisions.
Accordingly, the acceptability of pharmacotherapy and alternative treat ment modalities to the patient is one cri terion on which to base decisions to pre scribe medication. Another might be the presence of significantly severe comor bid psychiatric conditions that are responsive to medications that also treat PTSD. Medication might also be favored as a first line choice when the intensity of PTSD and/or comorbid depression or anxiety symptoms are interfering with a patient's ability to engage in, or tolerate, a psychotherapeutic intervention. Med ication treatment may also be indicated when there is no access to competent PTSD-focused psychotherapy and when symptoms persist beyond a reasonable course of treatment.
In What Medications Can We Have Confidence?
At present two medications, the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine, have received approval from the US Food and Drug Administration as indicated treat ments for PTSD. Favorable results with other SSRIs such as fluoxetine, fluvox amine, and citaloprarn have also been reported. In addition to their broad-spec trum capacity to reduce the severity of all three PTSD symptom clusters, SSRIs have other beneficial properties such as efficacy against disorders frequently comorbid with PTSD (eg, depression, panic disorder, social phobia, and obses sive-compulsive disorder), enhancement of global function, reduction of associat ed symptoms (eg, suicidality, aggressiv ity, impulsivity), and a low profile of side effects. Selective serotonin reup take inhibitors are clearly first line treat ment for PTSD.[ 2 , 3 ] Older antidepressants (eg, tricyclic antidepressants [TCAs] and monoamine oxidase inhibitors [MAOis] ) have also proven to be effective treatments for PTSD but are less preferred by clinicians because of side effects and because data supporting their efficacy is limit ed. On the other hand, randomized clinical trials with newer antidepressants (eg, nefazadone, ven lafaxine, and bupropion) are currently in progress and there are reports of pos itive results from open label trials with these agents. 4 Other classes of medications have not been tested as definitively as the afore mentioned antidepressants, although there are both theoretical and empirical reasons to consider anti-adrenergic agents (eg, clonidine, propranolol, guanfacine, and prazosin), anticonvulsants/mood sta bilizers (eg, carbamazepine, valproate, lamotrigine, and gabapentin), and atypi cal antipsychotic agents (eg, risperidone and olanzapine).[ 2, 3] It must be emphasized that benzodi azepines do not appear to have specific efficacy for PTSD symptoms, [ 5 ] although they can improve sleep and improve generalized anxiety.
Research on medication for children with PTSD is quite limited (for review see Donnelley and Amaya-Jackson [1] ). Children present unique challenges in that their PTSD may be comorbid with attention-deficit/hyperactivity disorder, school phobia, illicit drug use. and other externalizing, disruptive, or oppositional defiant disorders. Often, it is the disrup tive behavior, aggressiveness, or impul sive acting out in children with PTSD that is the chief treatment target. Help ing children to gain better self-control through treatment of these externalizing behavioral symptoms with stimulants (dextroamphetamine or methyl phenidate), alpha-2 agonists (clonidine or guanfacine), or the antidepressant bupropion, is often a precursor to the treatment of their PTSD per se. As discussed below, children merit special consideration in the pharmacologic management of PTSD and often require the use of multiple medications.
Do Medications Have a Role In

Alleviating Acute Traumatic Distress and Preventing PTSD?
We are at a preliminary stage in research on acute pharmacotherapy as an early intervention for acutely trauma tized individuals, with very little scien tific information to guide us.
It is reasonable to postulate that antidepressant medications, for which there is demonstrated efficacy in PTSD (see below), could be useful in an early stage of the disorder. The only pub lished data concerns the treatment of children with acute stress disorder related to burn injuries in which 83% of the 12 cases treated with imipramine responded favorably, in comparison to only 38% of the 13 cases who received chloral hydrate.
[ 6 ] Although one might expect that ben zodiazepines would ameliorate acute traumatic distress, this was not demon strated in the published controlled study of this question which involved alprazo lam and clonazepam. 7 Based on findings linking noradren ergic activity to fear-enhanced memory, Pitman and colleagues conducted a placebo-controlled trial of propranolol administered to emergency department patients. [8] Propranolol intervention ex-hibited a beneficial trend, although most statistical comparisons were nonsignifi cant. However, it is interesting that early propranolol treatment significantly reduced physiological reactivity to trau ma stimuli among the patients who received this medication shortly after their acute traumatization.
What Is the Best Way to Monitor Clinical Response and to Determine an Adequate Response to Treatment?
Strictly speaking, clinical response is best monitored with instruments that measure PTSD symptom severity. There is a wide choice of both self-rat ing scales and structured clinical inter views that may be used with both adults and children. Selection of a given instrument will depend on the balance between time available, patient compliance, clinical concerns, and sci entific necessity.
For rigorous research protocols, we recommend more labor-intensive struc tured interviews such as the Clinician Administered PTSD Scale (CAPS) 9 or PTSD Symptom Scale Interview (PSS I) [10] for adults or CAPS for Children (CAPS-C) [11] that provide greater com pleteness and accuracy in exchange for the extra effort. There are also a number of reliable and valid self-rating ques tionnaires for measuring PTSD symp tom severity that have good psychomet ric properties. [11] [12] [13] Since PTSD is usually associated with comorbid diagnoses and impaired functional status, it is not uncommon to monitor other psychopathological indices along with PTSD per se. It has become state of the art for treatment tri als for PTSD to define optimal out comes in terms of reduced severity of anxiety and depression in addition to PTSD per se, global improvement, and to include measurement of general func tion and quality of life.
What Are the Major Considerations Regarding Medication Tolerability for PTSD Patients?
Medication tolerability affects adher ence to pharmacotherapy over the course of treatment. There may be ways in which specific tolerability issues for psychiatric med ications interact with the diagnosis of PTSD. For example, the sexual side effects of SSRIs may serve as barriers to sexual intimacy within the context of PTSD-related emotional numbing and diminished closeness with others. It is important that clinicians inform patients of these potential side effects and assess the status of sexual functioning on an ongoing basis. Another tolerability con cern is the propensity for SSRIs and other antidepressants to produce activa tion side effects which may exacerbate PTSD-related arousal symptoms. It is therefore prudent to adopt the strategy of "starting low and going slow" with potentially activating medications because they may exacerbate or produce physical restlessness and insomnia dur ing the course of treatment.
What's the Next
Step When the Response to First Line Medications Is Inadequate?
It is important at the outset to define realistic goals for treatment that are both desirable and obtainable. [18] Although clinical trials tend to emphasize reduc tion in PTSD symptom severity, it may be that the management of suicidal behavior, substance misuse, social isola tion, and comorbid psychopathology is the first order of business, and improve ments in global function and quality of life the ultimate goal.
When treatment goals are achieved, medication should be continued for a reasonable interval (see question below). When treatment has been com pletely ineffective or has produced intol erable side effects it should be discon tinued. A more typical scenario is when an adequate clinical trial of a medication has been partially successful but improvement falls far short of treatment goals and the clinician is faced with the decision of whether to switch from or add to the initial medication. If further improvement is achieved after adding a medication, it is important to determine ultimately whether the improvement was related to the second medication alone or the combination. Such determi nations are aided by gradually reducing the initial medication with the patient's consent while monitoring clinical status. Due to the diffuse nature and frequent partial responsiveness of symptoms that present with PTSD, and what appears to be frequent use of medication combina tions, periodic evaluation of ongoing efficacy is of paramount importance.
While recent trials have established SSRIs as first line medications for PTSD, there is little empirical research to guide choices for second line inter ventions, and it seems reasonable to consider the unique psychopathology of an individual patient to guide these deci sions. The following recommendations are based primarily on theoretical con siderations and clinical experience for second line interventions (some of which have previously been proposed elsewhere 1, 1 9 ), assuming that initial treatment was an SSRI: Patients who are excessively aroused, hyperreactive, or having disso ciative episodes might benefit from anti adrenergic agents (eg, clonidine, guan facine, propranolol, or prazosin).
Fearful hypervigilant, paranoid, and psychotic patients might benefit from atypical antipsychotic agents.
* Patients with comorbid major depression might benefit from TCAs, MAOIs, nefazadone, venlafaxine, or bupropion.
* Patients who had an excellent clini cal response to SSRI treatment but expe rienced intolerable side effects might ben efit from discontinuing the SSRI and switching to nefazadone (because of its 5 HT2 receptor antagonism). * Labile, impulsive, and/or aggres sive patients might benefit from anticon vulsant/mood stabilizers or atypical antipsychotic agents.
* Children and adolescents with impulsive, externalizing behavioral dis orders such as ADHD and ODD may benefit from treatment with stimulants, clonidine or bupropion.
* Children with sleep onset anxiety and, or traumatic nightmares may bene fit from imipramine.
How Should the Presence of Comorbid Disorders Influence Medication Choices?
There is a high likelihood that at least one other psychiatric condition will be present along with PTSD.
[ 20 ] The presence of such associated disorders will often influence the choice of medication select Relapse rates were quite low in the subgroup that achieved initial remission status quickly.
ed to treat PTSD. Comorbid conditions, such as depression or anxiety, or specific trauma related symptoms, such as insom nia, may suggest a wide variety of treat ment options for clinicians to consider for initial medication intervention. As a general principle, broad-spec trum agents such as SSRIs are a good first choice. Selective serotonin reuptake inhibitors have efficacy in treating both the core symptoms of PTSD and condi tions such as the anxiety disorders and depression which commonly co-occur with PTSD. These agents also improve social and occupational functioning as well as an individual's perception of improved quality of life.[
-1 6] Although
SSRIs are generally effective for a broad spectrum of problems, clinicians should systematically monitor for the persis tence of symptoms not responsive to these agents. For example, despite sig nificant improvements in core PTSD symptoms in one study using sertraline, little improvement was seen in patients' comorbid anxiety and depressive symp toms. [1 5 ] This finding demonstrates the value of continuous symptom monitor ing and shows that residual or comorbid symptoms may require a different med ication to augment effective SSRI treat ment for PTSD.
How Long Do You Continue Medications for PTSD?
Evidence from treatment research for other disorders indicates that long term medication use prevents relapse of a number of chronic psychiatric disor ders. A recent report on continuation treatment for PTSD with the SSRI ser traline suggests that this may also be the case for PTSD.[ 2 1] In this study, PTSD patients who had had a success ful response to sertraline after 36 weeks of treatment were randomized to either sertraline or placebo groups for an additional 28 weeks of pharma cotherapy. Patients in the sertraline continuation group exhibited a relapse rate of only 5% in contrast to the 26% relapse rate observed among patients who had been switched from sertraline to placebo. This study shows that for some patients, sustaining medication treatment for 64 weeks produced a lower relapse rate than when similar treatment was provided for a shorter period of time. It is noteworthy that relapse rates were quite low in the sub group that achieved initial remission status quickly (within 4 weeks of start ing sertraline treatment). Therefore, treatment duration exceeding 1 year may thus be beneficial in many cases but individuals who exhibit robust or rapid responses should be given con sideration for shorter durations of med ication treatment.
Are There Special Considerations for Treating Children and Adolescents?
In terms of pharmacologic treatment, children are not simply small adults. Medications may have different effica cy, side-effect profiles, and may be metabolized differently in children ver sus adults. 22 Selective serotonin reup take inhibitors are typically dosed lower for children than for adults at the outset of treatment (eg, fluoxetine 5 mg/d or ser traline 25 mg/d) with slower upward titration, although higher doses, equiva lent to those used in adults, may ulti mately be needed for optimum symptom control. The stimulants (methyl phenidate, dextroamphetamine, mixed dextroamphetamine salts) and alpha-2 ago nists (clonidine and guanfacine) that tar get specific externalizing behavior disor ders common in children with PTSD, such as attention-deficit/hyperactivity disorder and oppositional defiant disor der, may need to be used along with other agents that treat core PTSD symptoms.
How and When Do You Integrate Medication Treatment With Psychotherapy?
Although all published PTSD treat ment research has focused on monother apy (eg, treatment with either a single medication or a single psychotherapeu tic approach), most patients who are prescribed medication in clinical prac tice also receive a psychosocial inter vention. There is no empirical evidence comparing monotherapy to combined treatments; therefore it is not known whether there is added benefit from combining treatments.
Without empirical evidence to guide us, a systematic approach where only one treatment component is changed at a time can be helpful for determining the need for combined approaches. If the ini tial therapeutic approach (medication or psychotherapy) is completely successful, there is no need for an additional treat ment. If the initial treatment is complete ly unsuccessful, it should be discontin ued so something else can be tried.
If, however, the initial treatment is partially successful following an ade quate therapeutic trial, the optimal approach may be to maintain the initial treatment (eg, medication) and add a second (eg, cognitive behavioral thera py). If combined treatment produces complete remission of PTSD-related problems, it is worthwhile to determine whether both treatments are needed to maintain this clinical improvement.
Where Do We Go From Here?
We are on the threshold of a very exciting period in the development and testing of pharmacotherapeutic agents for PTSD. Without exception, every medication that has been discussed in this article was originally developed as treatment for some other psychiatric or medical disorder and later tested with PTSD patients. Most of these medications were initially developed and marketed for treating depression (eg, SSRIs, TCAs, MAOis, etc.) although anticonvulsants/mood stabi lizers, anxiolytics, antiadrenergic agents, and atypical antipsychotics have also been mentioned.
Our expanding scientific understand ing of the pathophysiology of PTSD continues to suggest novel targets for pharmacological interventions. These include corticotropin-releasing-factor antagonists, neuropeptide Y agonists, selective serotonergic agents (eg, 5 HTIA agonists), selective opioid agents, substance P antagonists, glutamatergic modulators, and brain-derived neu rotropic factor enhancers. 29 In short, we can look forward to a future in which PTSD pharmacotherapy will employ medications that have been specifically designed and selected to treat the unique patterns of psychobiological abnormalities associated with PTSD.
